Share on StockTwits

Hospira (NYSE:HSP) is set to issue its Q114 quarterly earnings data on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.49 per share and revenue of $1.02 billion for the quarter. Hospira has set its FY14 guidance at $2.00-2.25 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Hospira (NYSE:HSP) last released its earnings data on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.01. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts expect Hospira to post $2.12 EPS for the current fiscal year and $2.31 EPS for the next fiscal year.

Hospira (NYSE:HSP) opened at 44.20 on Tuesday. Hospira has a 52 week low of $30.96 and a 52 week high of $45.24. The stock has a 50-day moving average of $42.99 and a 200-day moving average of $41.95. The company’s market cap is $7.358 billion.

A number of analysts have recently weighed in on HSP shares. Analysts at Stifel Nicolaus initiated coverage on shares of Hospira in a research note on Thursday, April 17th. They set a “neutral” rating on the stock. On the ratings front, analysts at Sterne Agee initiated coverage on shares of Hospira in a research note on Wednesday, April 16th. They set a “neutral” rating and a $39.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Hospira in a research note on Tuesday, April 8th. They now have a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $43.14.

Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.